Trial · NCT02304367
Results by group301
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 301
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Mean Serum Phosphorus Levels Above 2.5 mg/dL at the Mid-Point of the Dose Intervals Between Baseline and Week 24 | Burosumab | 50.0 | 95% Confidence Interval 26.80 to 73.20 | percentage of participants | |
| Change From Baseline to Week 48 in Osteoid Thickness | Burosumab | -5.12 | 95% Confidence Interval -10.04 to -0.20 | µm | |
| Change From Baseline to Week 48 in Osteoid Surface/Bone Surface (OS/BS) | Burosumab | -0.18 | 95% Confidence Interval -13.86 to 13.50 | percentage of bone surface | |
| Change From Baseline to Week 48 in Osteoid Volume/Bone Volume (OV/BV) | Burosumab | -5.47 | 95% Confidence Interval -11.87 to 0.93 | percentage of bone volume | |
| Change From Baseline to Week 48 in Mineralization Lag Time (MLt) | Burosumab | -565.20 | 95% Confidence Interval -2037.42 to 907.02 | days | |
| Percentage of Participants Achieving Mean Serum Phosphorus Levels Above 2.5 mg/dL at the End of the Dose Intervals Between Baseline and Week 24 | Burosumab | 21.4 | 95% Confidence Interval 7.57 to 47.59 | percentage of participants | |
| Mean Change From Baseline in Serum Phosphorus Levels at the Mid-Point of the Dose Interval, as Averaged Across Dose Cycles Between Baseline and Week 24 | Burosumab | 1.039 | Standard Deviation 0.5622 | mg/dL | |
| Percent Change From Baseline in Serum Phosphorus Levels at the Mid-Point of the Dose Interval, as Averaged Across Dose Cycles Between Baseline and Week 24 | Burosumab | 69.77 | Standard Deviation 43.743 | percent change | |
| Mean Change From Baseline in Serum Phosphorus Levels at the End of the Dosing Cycle, as Averaged Across Dose Cycles Between Baseline and Week 24 | Burosumab | 0.550 | Standard Deviation 0.4260 | mg/dL | |
| Percent Mean Change From Baseline in Serum Phosphorus Levels at the End of the Dosing Cycle, as Averaged Across Dose Cycles Between Baseline and Week 24 | Burosumab | 38.56 | Standard Deviation 33.027 | percent change | |
| Time-Adjusted Area Under the Curve (AUC) of Serum Phosphorus Levels Between Baseline and Week 24 | Burosumab | 2.36 | Standard Deviation 0.632 | mg/dL | |
| Change From Baseline Over Time in Serum 1,25-dihydroxyvitamin D (1,25(OH)2D) Concentration | Burosumab | Week 24 | 9.90 | Standard Error 4.10 | pg/mL |
| Change From Baseline Over Time in Serum 1,25-dihydroxyvitamin D (1,25(OH)2D) Concentration | Burosumab | Week 48 | 10.49 | Standard Error 4.82 | pg/mL |
| Change From Baseline Over Time in Serum 1,25-dihydroxyvitamin D (1,25(OH)2D) Concentration | Burosumab | Week 96 | 4.28 | Standard Error 3.80 | pg/mL |
| Change From Baseline Over Time in Serum 1,25-dihydroxyvitamin D (1,25(OH)2D) Concentration | Burosumab | Week 144 | 3.15 | Standard Error 3.34 | pg/mL |
| Change From Baseline Over Time in Serum 1,25-dihydroxyvitamin D (1,25(OH)2D) Concentration | Burosumab | Week 168 | 4.91 | Standard Error 3.94 | pg/mL |
| Change From Baseline Over Time in Serum 1,25-dihydroxyvitamin D (1,25(OH)2D) Concentration | Burosumab | Week 192 | 0.67 | Standard Error 4.19 | pg/mL |
| Change From Baseline Over Time in Serum 1,25-dihydroxyvitamin D (1,25(OH)2D) Concentration | Burosumab | Week 216 | 9.78 | Standard Error 3.04 | pg/mL |
| Change From Baseline Over Time in Serum 1,25-dihydroxyvitamin D (1,25(OH)2D) Concentration | Burosumab | Week 240 | 6.56 | Standard Error 3.19 | pg/mL |
| Change From Baseline Over Time in Total Serum Fibroblast Growth Factor 23 (FGF23) Concentration | Burosumab | Week 24 | 246335.35 | Standard Error 61089.98 | pg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02304367/results